Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Clinical Trial Participation
Clinical trials are absolutely necessary in order to make sure a drug works as intended. However, such testing does involve risk, as recently illustrated by Celgene’s decision to stop administering Revlimid® (lenalidomide) in its Phase III ORIGIN® trial because of patient deaths. Suppose you fit a clinical trial’s patient requirements: Would you take the risk?